Cargando…
Personalized Selection of a CFTR Modulator for a Patient with a Complex Allele [L467F;F508del]
The presence of complex alleles in the CFTR gene can lead to difficulties in diagnosing cystic fibrosis and cause resistance to therapy with CFTR modulators. Tezacaftor/ivacaftor therapy for 8 months in a patient with the initially established F508del/F508del genotype did not lead to an improvement...
Autores principales: | , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9600521/ https://www.ncbi.nlm.nih.gov/pubmed/36286063 http://dx.doi.org/10.3390/cimb44100349 |
_version_ | 1784816863559024640 |
---|---|
author | Kondratyeva, Elena Bulatenko, Nataliya Melyanovskaya, Yuliya Efremova, Anna Zhekaite, Elena Sherman, Viktoriya Voronkova, Anna Asherova, Irina Polyakov, Alexander Adyan, Tagui Kovalskaia, Valeriia Bukharova, Tatiana Goldshtein, Dmitry Kutsev, Sergey |
author_facet | Kondratyeva, Elena Bulatenko, Nataliya Melyanovskaya, Yuliya Efremova, Anna Zhekaite, Elena Sherman, Viktoriya Voronkova, Anna Asherova, Irina Polyakov, Alexander Adyan, Tagui Kovalskaia, Valeriia Bukharova, Tatiana Goldshtein, Dmitry Kutsev, Sergey |
author_sort | Kondratyeva, Elena |
collection | PubMed |
description | The presence of complex alleles in the CFTR gene can lead to difficulties in diagnosing cystic fibrosis and cause resistance to therapy with CFTR modulators. Tezacaftor/ivacaftor therapy for 8 months in a patient with the initially established F508del/F508del genotype did not lead to an improvement in her condition—there was no change in spirometry and an increase in the patient’s weight, while there was only a slight decrease in NaCl values, measured by a sweat test. The intestinal current measurements of the patient’s rectal biopsy showed no positive dynamics in the rescue of CFTR function while taking tezacaftor/ivacaftor. The assumption that the patient had an additional mutation in the cis position was confirmed by sequencing the CFTR gene, and the complex allele [L467F;F508del] was identified. Based on the rescue of CFTR function by elexacaftor/tezacaftor/ivacaftor obtained using forskolin-induced swelling on intestinal organoids, the patient was prescribed therapy with this targeted drug. The use of elexacaftor/tezacaftor/ivacaftor for 7 months resulted in a significant improvement in the patient’s clinical condition. |
format | Online Article Text |
id | pubmed-9600521 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-96005212022-10-27 Personalized Selection of a CFTR Modulator for a Patient with a Complex Allele [L467F;F508del] Kondratyeva, Elena Bulatenko, Nataliya Melyanovskaya, Yuliya Efremova, Anna Zhekaite, Elena Sherman, Viktoriya Voronkova, Anna Asherova, Irina Polyakov, Alexander Adyan, Tagui Kovalskaia, Valeriia Bukharova, Tatiana Goldshtein, Dmitry Kutsev, Sergey Curr Issues Mol Biol Article The presence of complex alleles in the CFTR gene can lead to difficulties in diagnosing cystic fibrosis and cause resistance to therapy with CFTR modulators. Tezacaftor/ivacaftor therapy for 8 months in a patient with the initially established F508del/F508del genotype did not lead to an improvement in her condition—there was no change in spirometry and an increase in the patient’s weight, while there was only a slight decrease in NaCl values, measured by a sweat test. The intestinal current measurements of the patient’s rectal biopsy showed no positive dynamics in the rescue of CFTR function while taking tezacaftor/ivacaftor. The assumption that the patient had an additional mutation in the cis position was confirmed by sequencing the CFTR gene, and the complex allele [L467F;F508del] was identified. Based on the rescue of CFTR function by elexacaftor/tezacaftor/ivacaftor obtained using forskolin-induced swelling on intestinal organoids, the patient was prescribed therapy with this targeted drug. The use of elexacaftor/tezacaftor/ivacaftor for 7 months resulted in a significant improvement in the patient’s clinical condition. MDPI 2022-10-21 /pmc/articles/PMC9600521/ /pubmed/36286063 http://dx.doi.org/10.3390/cimb44100349 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Kondratyeva, Elena Bulatenko, Nataliya Melyanovskaya, Yuliya Efremova, Anna Zhekaite, Elena Sherman, Viktoriya Voronkova, Anna Asherova, Irina Polyakov, Alexander Adyan, Tagui Kovalskaia, Valeriia Bukharova, Tatiana Goldshtein, Dmitry Kutsev, Sergey Personalized Selection of a CFTR Modulator for a Patient with a Complex Allele [L467F;F508del] |
title | Personalized Selection of a CFTR Modulator for a Patient with a Complex Allele [L467F;F508del] |
title_full | Personalized Selection of a CFTR Modulator for a Patient with a Complex Allele [L467F;F508del] |
title_fullStr | Personalized Selection of a CFTR Modulator for a Patient with a Complex Allele [L467F;F508del] |
title_full_unstemmed | Personalized Selection of a CFTR Modulator for a Patient with a Complex Allele [L467F;F508del] |
title_short | Personalized Selection of a CFTR Modulator for a Patient with a Complex Allele [L467F;F508del] |
title_sort | personalized selection of a cftr modulator for a patient with a complex allele [l467f;f508del] |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9600521/ https://www.ncbi.nlm.nih.gov/pubmed/36286063 http://dx.doi.org/10.3390/cimb44100349 |
work_keys_str_mv | AT kondratyevaelena personalizedselectionofacftrmodulatorforapatientwithacomplexallelel467ff508del AT bulatenkonataliya personalizedselectionofacftrmodulatorforapatientwithacomplexallelel467ff508del AT melyanovskayayuliya personalizedselectionofacftrmodulatorforapatientwithacomplexallelel467ff508del AT efremovaanna personalizedselectionofacftrmodulatorforapatientwithacomplexallelel467ff508del AT zhekaiteelena personalizedselectionofacftrmodulatorforapatientwithacomplexallelel467ff508del AT shermanviktoriya personalizedselectionofacftrmodulatorforapatientwithacomplexallelel467ff508del AT voronkovaanna personalizedselectionofacftrmodulatorforapatientwithacomplexallelel467ff508del AT asherovairina personalizedselectionofacftrmodulatorforapatientwithacomplexallelel467ff508del AT polyakovalexander personalizedselectionofacftrmodulatorforapatientwithacomplexallelel467ff508del AT adyantagui personalizedselectionofacftrmodulatorforapatientwithacomplexallelel467ff508del AT kovalskaiavaleriia personalizedselectionofacftrmodulatorforapatientwithacomplexallelel467ff508del AT bukharovatatiana personalizedselectionofacftrmodulatorforapatientwithacomplexallelel467ff508del AT goldshteindmitry personalizedselectionofacftrmodulatorforapatientwithacomplexallelel467ff508del AT kutsevsergey personalizedselectionofacftrmodulatorforapatientwithacomplexallelel467ff508del |